New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 18, 2014
08:50 EDTINSMInsmed breakthrough designation a 'game changer,' says Piper Jaffray
Piper Jaffray views the breakthrough designation for Arikayce for the treatment of nontuberculous mycobacterial as a "game changer" for Insmed. Piper expects shares to move sharply higher today and says the news brings the company "another important step closer toward approval." It reiterates an Overweight rating on Insmed with a $51 price target. The stock is up 27% in pre-open trading to $15.82.
News For INSM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 24, 2015
13:54 EDTINSMInsmed personnel strong, says Piper Jaffray
After attending Insmed's analyst event, Piper says that the company has assembled a strong development and commercial team . The firm adds that the company has forged unique relationships with specialists and patients. It keeps an Overweight rating on the shares.
March 23, 2015
09:06 EDTINSMInsmed appoints Eugene Sullivan as Chief Medical and Scientific Officer
Subscribe for More Information
March 20, 2015
09:25 EDTINSMInsmed to host analyst and investor day
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use